Upadacitinib (Rinvoq, AbbVie) in Severe AA: Explore the Topline Phase 3 Data
Upadacitinib (Rinvoq, AbbVie) performed well in severe alopecia areata (AA), according to topline data from the first of two pivotal studies of the Phase 3 UP-AA clinical program, The study evaluated the safety and efficacy of upadacitinib 15mg and 30mg, taken once daily, in adult and adolescent patients with severe alopecia areata (AA) characterized by […]